Clinical Features and Risk Factors of Adrenal Insufficiency in Patients With Cancer Admitted to the Hospitalist-Managed Medical Unit

Background The symptoms of adrenal insufficiency (AI) overlap with the common effects of advanced cancer and chemotherapy. Considering that AI may negatively affect the overall prognosis of cancer patients if not diagnosed in a timely manner, we analyzed the incidence, risk factors, and predictive methods of AI in cancer patients. Methods We retrospectively analyzed the medical records of 184 adult patients with malignancy who underwent a rapid adrenocorticotrophic hormone stimulation test in the medical hospitalist units of a tertiary hospital. Their baseline characteristics and clinical features were evaluated, and the risk factors for AI were identified using logistic regression analysis. Results Of the study patients, 65 (35%) were diagnosed with AI, in whom general weakness (63%) was the most common symptom. Multivariate logistic regression showed that eosinophilia (adjusted odds ratio [aOR], 4.28; 95% confidence interval [CI], 1.10–16.63; P = 0.036), history of steroid use (aOR, 2.37; 95% CI, 1.10–5.15; P = 0.028), and history of megestrol acetate use (aOR, 2.71; 95% CI, 1.38–5.33; P = 0.004) were associated with AI. Baseline cortisol levels of 6.2 μg/dL and 12.85 μg/dL showed a specificity of 95.0% and 95.4% for AI diagnosis, respectively. Conclusion AI was found in about one-third of patients with cancer who showed general symptoms that may be easily masked by cancer or chemotherapy, suggesting that clinical suspicion of AI is important while treating cancer patients. History of corticosteroids or megestrol acetate were risk factors for AI and eosinophilia was a pre-test predictor of AI. Baseline cortisol level appears to be a useful adjunct marker for AI.

[1]  Ho-Cheol Kang,et al.  Prevalence and Risk Factors for Adrenal Insufficiency in Patients with Multiple Myeloma Receiving Long-Term Chemotherapy including Corticosteroids: A Retrospective Cohort Study , 2021, BioMed Research International.

[2]  H. Sørensen,et al.  Management of endocrine disease: Glucocorticoid-induced adrenal insufficiency: Replace while we wait for evidence? , 2021, European journal of endocrinology.

[3]  Ho-Cheol Kang,et al.  Adrenal insufficiency in hospitalized patients with multiple myeloma , 2020, Leukemia & lymphoma.

[4]  B. Mendonca,et al.  Adrenal Insufficiency and Glucocorticoid Use During the COVID-19 Pandemic , 2020, Clinics.

[5]  F. Kuang Approach to Patients with Eosinophilia. , 2020, The Medical clinics of North America.

[6]  A. Tirosh,et al.  Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors. , 2019, Autoimmunity reviews.

[7]  W. Manosroi,et al.  Diagnostic performance of basal cortisol level at 0900-1300h in adrenal insufficiency , 2019, PloS one.

[8]  Junhwan Kim The Impact of Hospitalist Care in Korea , 2019, Journal of Korean medical science.

[9]  K. Boelaert,et al.  Glucocorticoid induced adrenal insufficiency is common in steroid treated glomerular diseases - proposed strategy for screening and management , 2019, BMC Nephrology.

[10]  H. Hirai,et al.  Late onset adrenal insufficiency after adrenalectomy due to latent nonclassical 21-hydroxylase deficiency , 2018, Medicine.

[11]  S. Lightman,et al.  Role of glucocorticoid negative feedback in the regulation of HPA axis pulsatility , 2018, Stress.

[12]  W. Miller The Hypothalamic-Pituitary-Adrenal Axis: A Brief History , 2018, Hormone Research in Paediatrics.

[13]  S. Doucette,et al.  The effect of time of day testing and utility of 30 and 60 minute cortisol values in the 250 mcg ACTH stimulation test. , 2018, Clinical biochemistry.

[14]  A. Pontecorvi,et al.  Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis , 2017, International journal of molecular sciences.

[15]  Ho Lam Chan,et al.  Immune checkpoint inhibitors: basics and challenges. , 2019, Current medicinal chemistry.

[16]  H. Koeppen,et al.  Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor , 2016, mAbs.

[17]  M. Oray,et al.  Long-term side effects of glucocorticoids , 2016, Expert opinion on drug safety.

[18]  J. Taube,et al.  PD-1/PD-L1 inhibitors. , 2015, Current opinion in pharmacology.

[19]  María Argente-Pla,et al.  Adrenal insufficiency induced by megestrol acetate: Report of two cases. , 2015, Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion.

[20]  S. Lightman,et al.  Understanding drug resistance to biologic therapy Dynamic regulation of glucocorticoid signalling in health and disease RHEUMATOLOGY , 2011 .

[21]  P. Reddy Clinical approach to adrenal insufficiency in hospitalised patients , 2011, International journal of clinical practice.

[22]  Á. HeRReRa-gómez,et al.  Hypoalbuminemia in Critically Ill Patients With Cancer: Incidence and Mortality , 2011, The American journal of hospice & palliative care.

[23]  M. Milas,et al.  Unrecognized adrenal insufficiency in patients undergoing laparoscopic adrenalectomy , 2009, Surgical Endoscopy.

[24]  O. Kämpe,et al.  Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency , 2008, Clinical endocrinology.

[25]  C. Paramo,et al.  Megestrol acetate-induced adrenal insufficiency , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[26]  D. Bulchandani,et al.  Megestrol acetate-associated adrenal insufficiency. , 2008, The American journal of geriatric pharmacotherapy.

[27]  G. Johannsson,et al.  Premature mortality in patients with Addison's disease: a population-based study. , 2006, The Journal of clinical endocrinology and metabolism.

[28]  R. Wachter An Introduction to the Hospitalist Model , 1999, Annals of Internal Medicine.

[29]  C. Haanen,et al.  Relative eosinophilia and functional adrenal insufficiency in critically ill patients. , 1999, Lancet.

[30]  M. Yu,et al.  Eosinophilia as a marker of adrenal insufficiency in the surgical intensive care unit. , 1996, Journal of the American College of Surgeons.

[31]  B. Redman,et al.  Prospective evaluation of adrenal insufficiency in patients with adrenal metastasis , 1987, Cancer.